ImmunoPrecise Antibodies Ltd.
IPA
$3.20
$0.5721.67%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.18% | -225.65% | -70.14% | -28.00% | 3.94% |
| Total Depreciation and Amortization | -10.66% | 15.50% | 6.76% | 3.18% | 3.84% |
| Total Amortization of Deferred Charges | -77.89% | -80.70% | -81.85% | -83.06% | -84.19% |
| Total Other Non-Cash Items | 17.82% | 926.56% | 274.90% | 285.16% | 342.94% |
| Change in Net Operating Assets | -84.56% | -3.21% | 195.49% | 641.94% | 170.12% |
| Cash from Operations | -96.13% | -75.48% | -4.19% | 56.36% | 84.40% |
| Capital Expenditure | 44.57% | -112.38% | -12.19% | 2.56% | 7.78% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 100.00% | 100.00% | 100.00% | 75.42% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 145.56% | -200.00% | -150.62% | -115.67% |
| Cash from Investing | 50.52% | -71.51% | -16.41% | 22.72% | 21.62% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -17.77% | -1.76% | 3.46% | 9.72% | -0.15% |
| Issuance of Common Stock | 418.14% | 1,356.84% | 3,845.92% | 377.55% | 229.61% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,315.39% | 3,366.40% | 566.14% | 566.17% | 261.99% |
| Foreign Exchange rate Adjustments | 60.94% | -1,533.28% | -561.80% | -263.87% | -247.64% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 242.81% | 222.13% | 72.70% | 77.74% | 78.35% |